Noida, May 19 (APAC Media): Zydus Lifesciences Limited on Tuesday reported a 14.6% rise in consolidated net profit for the March quarter, at Rs 15,929 crore, compared with Rs 13,905 crore in the same quarter of the previous fiscal year, the company said.
The company’s revenue rose 16.2% to Rs 75,870 crore, compared with Rs 65,279 crore in the same period last year.
EBITDA rose 20.2% to Rs 25,544 crore, compared with Rs 21,255 crore in the corresponding quarter of the previous year.
“We closed FY26 on a strong note, delivering on our commitments – both on revenue growth and profitability. We are confident our pipeline will drive overall growth visibility while future growth engines begin to deliver. Our near-term priorities are clear: maintain consistent quality standards, integrate our recent acquisitions, and capture synergies swiftly. Finally, our strong balance sheet ensures we have the flexibility to invest and strengthen our businesses further,” said Sharvil Patel, Managing Director, Zydus Lifesciences Limited.
Zydus Lifesciences Limited’s Board has approved a buyback of equity shares for an aggregate amount of up to Rs 11,000 million, at a price of Rs 1,150 per share, representing a 16% premium to the closing price on May 18, 2026.
Pharma Leader reported steady performance in its India formulations (pharmaceuticals) business, with revenues rising 14% year-on-year to Rs 17,528 million, accounting for 24% of consolidated revenues.
The branded business grew 15% year-on-year, outperforming the market, supported by strong traction in chronic therapies, which continued to expand at a faster pace and drove overall growth.
The company outpaced IPM growth across key therapy areas, including cardiology, respiratory and dermatology, as well as super-speciality segments such as oncology and nephrology. In oncology, it retained its leadership position in the super-speciality space.
The chronic portfolio share continued its steady expansion, rising to 46.3%, an increase of 620 basis points over the past three years, according to IQVIA MAT March 2026 data.
Zydus Lifesciences Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. Established in 1952, the company formerly known as Cadila Healthcare is engaged in the research, development, manufacturing and marketing of formulations, active pharmaceutical ingredients (APIs), vaccines and wellness products.
Disclaimer: Views expressed are those of experts and do not reflect APAC Media. This is for informational purposes only, not financial advice. We are not responsible for investment decisions. Please consult a qualified financial advisor before investing.
Also Read:
Centre Imposes Rs 3/Litre Petrol Export Duty, Slashes Diesel, ATF Levies
Discussion about this post